Michael Freeman

John Newman

Patrick Trucchio

Carvey Leung

Luis Santos

Michael Okunewitch

Rahul Sarugaser

Soumit Roy

- Oncolytics Biotech Inc. provided an update on the **GOBLET trial**, which evaluates pelareorep in gastrointestinal cancers, detailing enrollment progress, U.S. site expansion, and anticipated data readouts.  **[1129928_0001129928-25-000077_gobletupdate.htm:0]** 
- Enrollment for **Cohort 4 (SCAC)** is at **20 evaluable patients** and is expected to be completed by the **end of 2025**, with an efficacy update (ORR) anticipated in the **fourth quarter of 2025**.  **[1129928_0001129928-25-000077_gobletupdate.htm:0]** 
- **Cohort 5 (mPDAC)** enrollment is approximately **40% complete** and projected to be fully enrolled by the **end of 2026**, with an interim efficacy update, including overall survival, expected in the **first quarter of 2026**.  **[1129928_0001129928-25-000077_gobletupdate.htm:0]** 
- The GOBLET study is expanding to include **U.S. clinical sites**, with Northwestern University and other academic institutions expected to serve as participants.  **[1129928_0001129928-25-000077_gobletupdate.htm:0]**

Oncolytics Biotech Updates GOBLET Study Progress and U.S. Site Expansion

- Oncolytics Biotech provided an update on the GOBLET trial, which is evaluating **pelareorep** in gastrointestinal cancers.  **[1129928_20250916LN74592:0]** 
- For **Cohort 4 (Squamous Cell Carcinoma of the Anal Canal)**, pelareorep demonstrated a **33% overall response rate (ORR)** in 12 patients, with enrollment of 20 evaluable patients expected to be completed by the **end of 2025** and an efficacy update anticipated in **Q4 2025**.  **[1129928_20250916LN74592:0]** 
- Enrollment for **Cohort 5 (Metastatic Pancreatic Ductal Adenocarcinoma)** is **approximately 40% complete** and projected to be fully enrolled by the **end of 2026**, with an interim efficacy update, including overall survival, expected in **Q1 2026**.  **[1129928_20250916LN74592:0]** 
- The company is expanding the GOBLET study to **U.S. clinical sites**, having submitted a protocol amendment, with Northwestern University expected to serve as one of the sites.  **[1129928_20250916LN74592:0]**

- Oncolytics Biotech Inc. provided an updated safety analysis for **pelareorep**, an intravenously delivered double-stranded RNA immunotherapeutic agent.  **[1129928_0001129928-25-000072_oncypooledsafetypr.htm:0]** 
- The analysis, which includes data from **over 1,200 patients** dosed with pelareorep (including **over 300 gastrointestinal cancer patients**), continues to demonstrate a **favorable safety profile** across multiple indications and treatment combinations.  **[1129928_0001129928-25-000072_oncypooledsafetypr.htm:0]** 
- The most frequent adverse events observed were **Grade 1 and 2 flu-like symptoms** (fever, chills, fatigue) and gastrointestinal issues (nausea, vomiting, diarrhea), with **neutropenia** also noted in GI tumor patients.  **[1129928_0001129928-25-000072_oncypooledsafetypr.htm:0]** 
- The company's CEO stated that pelareorep represents **one of the most de-risked immunotherapies** not yet approved, and Oncolytics is moving towards **registration-enabled studies** and actively pursuing strategic partnerships.  **[1129928_0001129928-25-000072_oncypooledsafetypr.htm:0]**

ONCOLYTICS BIOTECH (ONCY)